Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, announces that Eroxon® has won the “New Product of the Year, Healthcare” category at the Boots Supplier Awards 2023, following its UK launch earlier this year. The award is further recognition for Futura’s breakthrough treatment for erectile dysfunction (“ED”) as it provides an […]
Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, today announces that the Mexican Secretariat of Health has granted over the counter sale (“OTC”) Marketing Authorisation for Eroxon®, the Company’s breakthrough, topical gel formulation for the treatment of erectile dysfunction (“ED”). Read more…
Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, today announces that Eroxon® is now available for purchase online through the BinSina Pharmacy in the United Arab Emirates, the first market in the Middle East to stock the product. Read more…
Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, today announces that it has been granted allowance of its EU patent which will provide protection for MED3000 until 2040 in all European markets. In all other key ED markets including the US, the Company is continuing to prosecute patent applications to provide […]
Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, is pleased to announce its unaudited interim results for the six months ended 30 June 2023 (“H1 2023”). MED3000, under the brand name Eroxon®, is the first pan-European clinically proven topical treatment for Erectile Dysfunction (“ED”) available without the need of a doctor’s prescription […]
